Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alissa Poh

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Cancer Discovery|December 15, 2015
Multiple Myeloma Gets Three New DrugsAlissa Poh
Cancer Discovery|December 2, 2015
Novartis Compiles Mouse Avatar "Encyclopedia"Alissa Poh
Cancer Discovery|March 10, 2016
How Ovarian Cancer Evades Immune ScrutinyAlissa Poh
Cancer Discovery|March 11, 2016
Boosting the Potency of T-cell TherapiesAlissa Poh
Cancer Discovery|November 11, 2015
First Oncolytic Viral Therapy for MelanomaAlissa Poh
Cancer Discovery|February 13, 2016
Accelerating Lead Compound OptimizationAlissa Poh
Cancer Discovery|January 14, 2015
In search of exceptional respondersAlissa Poh
Cancer Discovery|February 27, 2016
Two Unique Glioma Subtypes RevealedAlissa Poh
Molecular Cancer Therapeutics|February 19, 2008
Defective p53 signaling in p53 wild-type tumors attenuates p21waf1 induction and cyclin B repression rendering them sensitive to Chk1 inhibitors that abrogate DNA damage-induced S and G2 arrestAime A Levesque, Andrew A Fanous, Alissa Poh, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Cancer Discovery|December 15, 2015
Multiple Myeloma Gets Three New DrugsAlissa Poh
Cancer Discovery|December 2, 2015
Novartis Compiles Mouse Avatar "Encyclopedia"Alissa Poh
Cancer Discovery|March 10, 2016
How Ovarian Cancer Evades Immune ScrutinyAlissa Poh
Cancer Discovery|March 11, 2016
Boosting the Potency of T-cell TherapiesAlissa Poh
Cancer Discovery|November 11, 2015
First Oncolytic Viral Therapy for MelanomaAlissa Poh
Cancer Discovery|February 13, 2016
Accelerating Lead Compound OptimizationAlissa Poh
Cancer Discovery|January 14, 2015
In search of exceptional respondersAlissa Poh
Cancer Discovery|February 27, 2016
Two Unique Glioma Subtypes RevealedAlissa Poh
Molecular Cancer Therapeutics|February 19, 2008
Defective p53 signaling in p53 wild-type tumors attenuates p21waf1 induction and cyclin B repression rendering them sensitive to Chk1 inhibitors that abrogate DNA damage-induced S and G2 arrestAime A Levesque, Andrew A Fanous, Alissa Poh, et al.
Pageof 1